Moss Genomics Launches "Perennial" Genomics Platform, Closes on 130 ETH
Moss Genomics (CSE: MOSS, OTCQB: MSSGF) has announced two significant developments: the public launch of its genomics platform 'Perennial' and the closure of a cryptocurrency financing round.
The Perennial platform, which completed beta testing in March, enables users to upload standard blood test results and receive personalized biomarker-based health insights. The platform is now accessible at app.mossgenomics.com.
Additionally, the company has secured 130 ETH (Ethereum) at CAD $3,500 per ETH as part of its ongoing private placement, raising gross proceeds of CAD $455,000. In exchange, Moss issued 2,527,777 common shares at CAD $0.18 per share. The securities are subject to a four-month plus one-day statutory hold period.
Moss Genomics (CSE: MOSS, OTCQB: MSSGF) ha annunciato due importanti novità: il lancio pubblico della sua piattaforma genomica 'Perennial' e la chiusura di un round di finanziamento in criptovalute.
La piattaforma Perennial, che ha completato la fase beta a marzo, consente agli utenti di caricare i risultati di analisi del sangue standard e ricevere approfondimenti personalizzati sulla salute basati su biomarcatori. La piattaforma è ora accessibile all'indirizzo app.mossgenomics.com.
Inoltre, l'azienda ha raccolto 130 ETH (Ethereum) al prezzo di 3.500 CAD per ETH nell'ambito di un collocamento privato in corso, raccogliendo proventi lordi pari a 455.000 CAD. In cambio, Moss ha emesso 2.527.777 azioni ordinarie a 0,18 CAD per azione. I titoli sono soggetti a un periodo di blocco legale di quattro mesi più un giorno.
Moss Genomics (CSE: MOSS, OTCQB: MSSGF) ha anunciado dos desarrollos importantes: el lanzamiento público de su plataforma genómica 'Perennial' y el cierre de una ronda de financiamiento en criptomonedas.
La plataforma Perennial, que completó la fase beta en marzo, permite a los usuarios subir resultados estándar de análisis de sangre y recibir información personalizada sobre la salud basada en biomarcadores. La plataforma ya está disponible en app.mossgenomics.com.
Además, la compañía ha asegurado 130 ETH (Ethereum) a 3,500 CAD por ETH como parte de su colocación privada en curso, recaudando ingresos brutos de 455,000 CAD. A cambio, Moss emitió 2,527,777 acciones ordinarias a 0.18 CAD por acción. Los valores están sujetos a un período de retención legal de cuatro meses más un día.
Moss Genomics (CSE: MOSS, OTCQB: MSSGF)가 두 가지 중요한 소식을 발표했습니다: 유전체 플랫폼 'Perennial'의 공개 출시와 암호화폐 자금 조달 라운드 종료입니다.
3월에 베타 테스트를 완료한 Perennial 플랫폼은 사용자가 표준 혈액 검사 결과를 업로드하고 바이오마커 기반의 개인 맞춤 건강 인사이트를 받을 수 있게 합니다. 해당 플랫폼은 현재 app.mossgenomics.com에서 이용 가능합니다.
또한, 회사는 진행 중인 사모 투자에서 ETH 130개(이더리움)를 ETH당 CAD 3,500의 가격으로 확보했으며, 총 455,000 CAD의 총 수익을 올렸습니다. 이에 대해 Moss는 주당 CAD 0.18에 2,527,777 보통주를 발행했습니다. 증권은 4개월 및 1일의 법적 보유 기간이 적용됩니다.
Moss Genomics (CSE : MOSS, OTCQB : MSSGF) a annoncé deux développements importants : le lancement public de sa plateforme génomique 'Perennial' et la clôture d'un tour de financement en cryptomonnaies.
La plateforme Perennial, qui a terminé sa phase bêta en mars, permet aux utilisateurs de télécharger des résultats d'analyses sanguines standard et de recevoir des informations personnalisées sur la santé basées sur des biomarqueurs. La plateforme est désormais accessible sur app.mossgenomics.com.
De plus, la société a sécurisé 130 ETH (Ethereum) au prix de 3 500 CAD par ETH dans le cadre de son placement privé en cours, levant ainsi un produit brut de 455 000 CAD. En échange, Moss a émis 2 527 777 actions ordinaires à 0,18 CAD par action. Les titres sont soumis à une période de blocage légale de quatre mois plus un jour.
Moss Genomics (CSE: MOSS, OTCQB: MSSGF) hat zwei bedeutende Entwicklungen bekannt gegeben: den öffentlichen Start seiner Genomik-Plattform 'Perennial' und den Abschluss einer Kryptowährungs-Finanzierungsrunde.
Die Perennial-Plattform, die im März die Betaphase abgeschlossen hat, ermöglicht es Nutzern, Standard-Bluttestergebnisse hochzuladen und personalisierte gesundheitsbezogene Einblicke basierend auf Biomarkern zu erhalten. Die Plattform ist jetzt unter app.mossgenomics.com zugänglich.
Zusätzlich hat das Unternehmen im Rahmen seiner laufenden Privatplatzierung 130 ETH (Ethereum) zu CAD 3.500 pro ETH gesichert und damit Bruttoerlöse von CAD 455.000 erzielt. Im Gegenzug hat Moss 2.527.777 Stammaktien zu je CAD 0,18 ausgegeben. Die Wertpapiere unterliegen einer gesetzlichen Haltefrist von vier Monaten plus einem Tag.
- Launch of new revenue-generating Perennial platform for consumer health insights
- Successful raise of CAD $455,000 (130 ETH) strengthening company's treasury
- Strategic positioning in both genomics and digital assets markets
- Dilution of existing shareholders through issuance of 2,527,777 new shares
- Exposure to cryptocurrency volatility risk through ETH-based financing
Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce the public launch of its genomics platform "Perennial", and closing on 130 ETH as part of its ongoing private placement.
Public Launch of Perennial
Moss is pleased to announce the public launch of its new genomics platform, "Perennial". The platform allows users to upload standard blood test results and receive deep insights personalized to their own biomarkers. Perennial, which had been in beta testing since March, represents the Company's next step toward unlocking consumer-facing, data-driven health insights. Consumers can try the product by visiting - https://app.mossgenomics.com/.
Closure of ETH Financing
The Company is also pleased to announce that it has closed on 130 ETH at a price of
This financing further supports Moss's strategic Ethereum treasury, which plays a central role in how the Company raises capital and manages its digital assets.
All securities issued under the private placement are subject to a statutory hold period expiring four months plus one day from the date of issuance.
The securities issued under the private placement have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States, or to, or for the account or benefit of, U.S. persons or persons in the United States, absent registration or an applicable exemption from the registration requirements.
About Moss Genomics Inc.
Moss Genomics is a biotechnology company focused on genomics and microbiome research to develop advanced genetic insights and solutions. The company leverages blockchain technology to enhance security and user control over genomic information. Along with its genomics-focused products, Moss Genomics deploys a crypto accumulation strategy as part of its treasury management, currently holding 290 ETH on its balance sheet.
For further information concerning Moss and its business, please view the Company's website at https://mossgenomics.com/ and its SEDAR+ profile at www.sedarplus.ca or contact us at:
CONTACT INFORMATION
Moss Genomics Inc.
Jack Liu, Chief Executive Officer and Director
Email: invest@mossgenomics.com
Telephone: 604-710-0124
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-Looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's intention to leverage the blockchain to advance its genomics business; the Company's belief that blockchain technology will enhance data security, privacy, and user control over genomic information; the Company's belief that its product offerings will make genetic insights more accessible and secure; the Company's belief that cryptocurrency will represent a viable alternative to traditional fiat currencies as part of the Company's treasury management system; and that the Company may close additional tranches under its ongoing private placement.
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the risk that the Company will be unable to utilize the blockchain in an effective manner for the advancement of its genomics business; the risk that the blockchain technology will not notably enhance data security, privacy or user control over genetic information; the risk that the Company's product offerings are unable to make genetic insights more accessible or secure; the risk that cryptocurrency will not represent a viable alternative to traditional fiat currencies for use in a treasury management system; and the risk that the Company will be unable to close additional tranches under its ongoing private placement.
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: blockchain technologies can be effectively implemented into the Company's genomics business model and can be implemented in a cost-effective and timely manner; the privacy and security offered by decentralized blockchain technology will be superior to the privacy and security over user data which may be available through other means; that the Company's use of blockchain as part of its business model will improve access to genetic insights; and that the use of cryptocurrency in the Company's treasury management system will reflect a viable alternative to traditional fiat currencies, including the risk that commercial partners of the Company are or become unwilling to accept cryptocurrency as consideration for products and services.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
Cryptocurrency Market Risks
The Company would like to remind investors that markets for cryptocurrencies have experienced much larger fluctuations than other markets, and there can be no assurances that significant swings in price will slow in the future. In the event that the price of cryptocurrencies decline, the value of an investment in the Company could also decline. As well, momentum pricing is typically associated with assets whose valuation, as determined by the investing public, accounts for anticipated future appreciation in value. Momentum pricing of cryptocurrency may result in speculation regarding future appreciation in the value of cryptocurrency. As a result, changing investor confidence could adversely affect an investment in the Company. Additionally, there is no assurance that cryptocurrency will become a leading means of digital payment. Any slowing or stopping of the development in the acceptance of cryptocurrency may adversely affect an investment in the Company. Furthermore, there is a risk that cryptocurrency trading platforms, or the Company's digital wallets may be compromised. Access to the Company's crypto-assets, maintained in a hosted online wallet, could also be restricted as a result of cyber crime. Any of these events may adversely affect the operations of the Company and, consequently, its business and profitability.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249949
FAQ
What is Moss Genomics' new Perennial platform and how does it work?
How much did Moss Genomics (MSSGF) raise in their latest ETH financing round?
What is the share price of MSSGF's latest private placement?
How long is the hold period for MSSGF's newly issued shares?
